An Open-Label, Multi-Centre Study to Evaluate the Safety, Tolerability and Immunogenicity of CSL's Influenza Vaccine in a Paediatric Population (greater than or equal to 6 Months to less than 9 Years of Age).
Phase of Trial: Phase III
Latest Information Update: 09 Aug 2016
At a glance
- Drugs Influenza virus vaccine (Afluria) (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors CSL
- 14 Jul 2008 New trial record.